Detalhe da pesquisa
1.
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
N Engl J Med
; 390(8): 723-735, 2024 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38381675
2.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet
; 401(10373): 269-280, 2023 01 28.
Artigo
Inglês
| MEDLINE | ID: mdl-36709073
3.
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
Haematologica
; 2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38299605
4.
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
Ann Hematol
; 103(1): 117-123, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38030891
5.
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
Ann Hematol
; 103(6): 1941-1945, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38634915
6.
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
Am J Hematol
; 99(6): 1040-1055, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38440831
7.
Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.
Ann Hematol
; 102(5): 985-993, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-36944847
8.
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.
Am J Hematol
; 98(12): E360-E363, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37705256
9.
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.
Cancer
; 128(19): 3495-3501, 2022 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35942592
10.
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.
Cancer
; 128(21): 3880-3887, 2022 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36107670
11.
Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
Br J Haematol
; 198(4): 713-720, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35751140
12.
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
Blood
; 135(19): 1696-1703, 2020 05 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32107559
13.
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Ann Hematol
; 101(1): 139-146, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34622316
14.
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(9): 1033-1062, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36075392
15.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Future Oncol
; 18(27): 2987-2997, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-35950489
16.
Stepping out of antiquity: An update on emerging drugs for the treatment of polycythemia vera.
Expert Opin Emerg Drugs
; 26(3): 209-218, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34139920
17.
Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.
Haematologica
; 105(2): 398-406, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-31073071
18.
What's in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia.
J Natl Compr Canc Netw
; 18(9): 1279-1284, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32886905
19.
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(9): 1248-1269, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32886902
20.
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
Biol Blood Marrow Transplant
; 25(6): 1142-1151, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30625392